Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06286046

A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy

A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy (RESIST)

Sponsor: Agios Pharmaceuticals, Inc.

Conditions Nephropathy Sickle Cell Disease

Interventions Mitapivat

Updated 21 times since 2024 Last updated: Feb 27, 2026 Started: Mar 31, 2026 Primary completion: May 31, 2027 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06286046, this PHASE2 trial focuses on Nephropathy and Sickle Cell Disease and remains actively recruiting participants. Sponsored by Agios Pharmaceuticals, Inc., it has been updated 21 times since 2026, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

21 versions recorded

Mar 2026 — Present [monthly]

Not Yet Recruiting PHASE2
Feb 2026 — Mar 2026 [monthly]

Not Yet Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2
Nov 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE2
Oct 2025 — Nov 2025 [monthly]

Not Yet Recruiting PHASE2

▶ Show 16 earlier versions

Sep 2025 — Oct 2025 [monthly]

Not Yet Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Not Yet Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE2
Apr 2025 — May 2025 [monthly]

Not Yet Recruiting PHASE2
Mar 2025 — Apr 2025 [monthly]

Not Yet Recruiting PHASE2
Dec 2024 — Mar 2025 [monthly]

Not Yet Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Not Yet Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
May 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE2
Apr 2024 — May 2024 [monthly]

Not Yet Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agios Pharmaceuticals, Inc.

Data source: Agios Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.